Methods for hematopoietic precursor mobilization

Patent metadata

Field	Value
Publication number	US-9610331-B2
Application number	US-201013394854-A
Country	US
Kind code	B2
Filing date	Sep 5, 2010
Priority date	Sep 8, 2009
Publication date	Apr 4, 2017
Grant date	Apr 4, 2017

Abstract

Methods of modulating mobilization of cells from the bone marrow are provided. In a specific embodiment there is provided a method of increasing mobilization of hematopoietic precursors from the bone marrow to the peripheral blood in a subject in need thereof, the method comprising: (a) administering to the subject an agent which downregulates an activity or expression of a coagulation factor or an effector thereof; and (b) harvesting the hematopoietic precursors from the peripheral blood.

First claim

What is claimed is:

1. A method of increasing mobilization of hematopoietic precursors from the bone marrow to the peripheral blood in a human subject, wherein the subject has a hematologic disorder or condition that is not Hodgkin's lymphoma, the method comprising:
(a) administering to the subject Clexane or Dabigatran;
(b) administering to the subject a mobilization factor comprising G-CSF;
(c) determining the efficacy of said mobilization; and subsequently
(d) harvesting said hematopoietic precursors from the peripheral blood, thereby increasing said mobilization of said hematopoietic precursors from said bone marrow to said peripheral blood in said human subject.

2. The method of claim 1 , wherein said subject is an autologous recipient subject.

3. The method of claim 1 , wherein said subject is in need of stem cell transplantation and said administering is effected prior to said transplantation.

4. The method of claim 1 , wherein said subject is in need of stem cell transplantation and said administering is effected subsequent to said transplantation.

5. The method of claim 1 , wherein said mobilization factor is administered in conjunction with said Clexane or said Dabigatran.

6. The method of claim 1 , wherein said administering is effected in a plurality of administrations, with a course of treatment lasting from several days to several weeks.

7. The method of claim 1 , wherein said determining said efficacy of said mobilization is effected by isolating a quantity of the patient's blood and analyzing the quantity of the hematopoietic precursor cells within the blood.

8. A method of increasing mobilization of hematopoietic precursors from the bone marrow to the peripheral blood in a healthy human subject, the method comprising:
(a) administering to the subject Clexane or Dabigatran;
(b) administering to the subject a mobilization factor comprising G-CSF;
(c) determining the efficacy of said mobilization; and subsequently
(d) harvesting said hematopoietic precursors from the peripheral blood, thereby increasing said mobilization of said hematopoietic precursors from said bone marrow to said peripheral blood in said healthy human subject.

9. The method of claim 8 , wherein said mobilization factor is administered in conjunction with said Clexane or said Dabigatran.

10. The method of claim 8 , wherein said administering is effected in a plurality of administrations, with a course of treatment lasting from several days to several weeks.

11. A method of increasing mobilization of hematopoietic precursors from the bone marrow to the peripheral blood in a human subject, wherein the subject has a hematologic disorder or condition that is not Hodgkin's lymphoma, the method comprising:
(a) administering to the subject Clexane or Dabigatran, wherein said administering is effected in a plurality of administrations, with a course of treatment lasting from several days to several weeks;
(b) administering to the subject a mobilization factor comprising G-CSF; and subsequently
(c) harvesting said hematopoietic precursors from the peripheral blood, thereby increasing said mobilization of said hematopoietic precursors from said bone marrow to said peripheral blood in said human subject.

Assignees

• Aronovich Anna
• Tchorsh-Yutsis Dalit
• Rechavi Gideon
• Reisner Yair
• Yeda Res & Dev
• Tel Hashomer Medical Res Infrastructure & Services Ltd

Inventors

• Aronovich Anna
• Tchorsh-Yutsis Dalit
• Rechavi Gideon
• Reisner Yair

Classifications

• A61K38/363 Primary

  Fibrinogen · CPC title

• A61K31/4439

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/727

  Heparin; Heparan · CPC title

• A61K38/37

  Factors VIII · CPC title